$Alphabet(GOOG)$ Google's core

$Alphabet(GOOG)$ Google's core business aside, PDSB and Patrick Soon's cancer platform looks stronger than HPV+ with 3x survival rates in head-to-head comparison. No FDA approved drugs, but double the response and survival rates for colorectal cancer. Very clean safety profile for this late-stage oncology platform, and excellent data in hard-to-treat prostate cancers. All trials were performed by NIC, NIH, Mayo, and MD Anderson. There could be a potential bidding war for the Versamune platform, with Merck, AbbVie, or Pfizer possibly outbidding Patrick Soon for it.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":610548240424984,"tweetId":"610548240424984","gmtCreate":1790064925000,"gmtModify":1790172598350,"author":{"id":10000000000010990,"idStr":"10000000000010990","authorId":10000000000010990,"authorIdStr":"10000000000010990","name":"Merle Ted","avatar":"https://static.tigerbbs.com/d0681550b13e51a8ffa4c08327616955","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":56,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/GOOG\">$Alphabet(GOOG)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;Google's core business aside, PDSB and Patrick Soon's cancer platform looks stronger than HPV+ with 3x survival rates in head-to-head comparison. No FDA approved drugs, but double the response and survival rates for colorectal cancer. Very clean safety profile for this late-stage oncology platform, and excellent data in hard-to-treat prostate cancers. All trials were performed by NIC, NIH, Mayo, and MD Anderson. There could be a potential bidding war for the Versamune platform, with Merck, AbbVie, or Pfizer possibly outbidding Patrick Soon for it.</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/GOOG\">$Alphabet(GOOG)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;Google's core business aside, PDSB and Patrick Soon's cancer platform looks stronger than HPV+ with 3x survival rates in head-to-head comparison. No FDA approved drugs, but double the response and survival rates for colorectal cancer. Very clean safety profile for this late-stage oncology platform, and excellent data in hard-to-treat prostate cancers. All trials were performed by NIC, NIH, Mayo, and MD Anderson. There could be a potential bidding war for the Versamune platform, with Merck, AbbVie, or Pfizer possibly outbidding Patrick Soon for it.</p></body></html>","text":"$Alphabet(GOOG)$ Google's core business aside, PDSB and Patrick Soon's cancer platform looks stronger than HPV+ with 3x survival rates in head-to-head comparison. No FDA approved drugs, but double the response and survival rates for colorectal cancer. Very clean safety profile for this late-stage oncology platform, and excellent data in hard-to-treat prostate cancers. All trials were performed by NIC, NIH, Mayo, and MD Anderson. There could be a potential bidding war for the Versamune platform, with Merck, AbbVie, or Pfizer possibly outbidding Patrick Soon for it.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/610548240424984","repostId":0,"isVote":1,"tweetType":1,"viewCount":289,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["GOOG"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":486,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/610548240424984"}